Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its growing pipeline and will continue to collaborate with industry partners to usher in a new ADC era. The company was founded in 2019 based on innovation coming out of the LMU Munich and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Berlin. Our growing team of chemists, biologists and executive leaders has since then advanced these technologies developing a new suite of additive technologies proprietary to Tubulis. Our deep scientific understanding of the field puts us in the unique position to build on the discoveries made over the past 20 years in the ADC space and translate this understanding into meaningful therapeutic benefits for patients.